u/Buy-NVDA · 30d agono track record yet
Ez money VRDN
Viridian Therapeutics released Phase 3 data for TED showing strong efficacy (p < 0.0001) with a potentially best-in-class safety profile versus Amgen's Tepezza. With $1.1B in cash, institutional backing at $17.00, and a June 30 PDUFA decision as a near-term catalyst, the stock—currently trading below the offering price—has upside to analyst targets of $34+.
At post $17.20Now $15.77-8.3% since postedas of Jun 10, 4:59 PM ET
1d-2.0%
3d+1.3%
1w-6.4%
1m-8.3%
3m—
6m—
1y—